Rafferty Asset Management, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Rafferty Asset Management, LLC

$26.8 Billion
Q2 2024

A detailed history of Rafferty Asset Management, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 149,599 shares of ARWR stock, worth $2.87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

149,599

Previous 274,159 45.43%

Holding current value

$2.87 Million

Previous $7.84 Million 50.41%

% of portfolio

0.01%

Previous 0.03%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$21.87 - $28.24 $2.72 Million - $3.52 Million	-124,560 Reduced 45.43%	149,599 $3.89 Million
Q1 2024 May 13, 2024	SELL	$27.21 - $39.48 $2.47 Million - $3.59 Million	-90,928 Reduced 24.91%	274,159 $7.84 Million
Q4 2023 Feb 13, 2024	BUY	$21.2 - $31.03 $1.43 Million - $2.09 Million	67,332 Added 22.61%	365,087 $11.2 Million
Q3 2023 Nov 13, 2023	BUY	$26.2 - $36.08 $1.64 Million - $2.26 Million	62,542 Added 26.59%	297,755 $8 Million
Q2 2023 Aug 11, 2023	SELL	$25.16 - $41.38 $684,804 - $1.13 Million	-27,218 Reduced 10.37%	235,213 $8.39 Million
Q1 2023 May 11, 2023	SELL	$23.68 - $38.51 $234,834 - $381,903	-9,917 Reduced 3.64%	262,431 $6.67 Million
Q4 2022 Feb 13, 2023	BUY	$28.0 - $40.56 $2.47 Million - $3.58 Million	88,381 Added 48.04%	272,348 $11 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $1.62 Million - $2.64 Million	54,579 Added 42.18%	183,967 $6.08 Million
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $60,276 - $109,773	-2,169 Reduced 1.65%	129,388 $4.56 Million
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $2.13 Million - $3.77 Million	53,832 Added 69.26%	131,557 $6.05 Million
Q4 2021 Feb 10, 2022	BUY	$58.09 - $82.51 $1.69 Million - $2.39 Million	29,024 Added 59.6%	77,725 $5.15 Million
Q3 2021 Nov 10, 2021	BUY	$58.38 - $84.96 $1.13 Million - $1.64 Million	19,293 Added 65.6%	48,701 $3.04 Million
Q2 2021 Aug 10, 2021	SELL	$62.15 - $90.32 $1.02 Million - $1.48 Million	-16,384 Reduced 35.78%	29,408 $2.44 Million
Q1 2021 May 10, 2021	BUY	$61.35 - $90.47 $2.04 Million - $3 Million	33,205 Added 263.8%	45,792 $3.04 Million
Q4 2020 Feb 10, 2021	SELL	$43.82 - $85.37 $2.07 Million - $4.03 Million	-47,158 Reduced 78.93%	12,587 $966,000
Q3 2020 Nov 13, 2020	BUY	$33.21 - $51.27 $1.01 Million - $1.57 Million	30,557 Added 104.69%	59,745 $2.57 Million
Q2 2020 Aug 07, 2020	BUY	$26.12 - $43.27 $580,752 - $962,065	22,234 Added 319.73%	29,188 $1.26 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $1.07 Million - $3.29 Million	-52,075 Reduced 88.22%	6,954 $200,000
Q4 2019 Feb 10, 2020	SELL	$28.14 - $73.01 $4.43 Million - $11.5 Million	-157,412 Reduced 72.73%	59,029 $3.74 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $1.31 Million - $1.74 Million	50,050 Added 30.08%	216,441 $6.1 Million
Q2 2019 Aug 09, 2019	SELL	$17.43 - $28.82 $658,139 - $1.09 Million	-37,759 Reduced 18.5%	166,391 $4.41 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $2.46 Million - $4.12 Million	204,150 New	204,150 $3.75 Million

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

92.3M

Call Options Held

1.33M

Put Options Held

549K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.03B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Arrowhead Pharmaceuticals, Inc. Transaction History